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Abstract
Background: Prostaglandin H2 (PGH2) is a common precursor for the synthesis of five different
Prostanoids via specific Prostanoid Synthases. The binding of this substrate with these Synthases is
not properly understood. Moreover, currently no crystal structure of complexes bound with PGH2
has been reported. Hence, understanding the interactions of PGH2 and characterizing its binding
sites in these synthases is crucial for developing novel therapeutics based on these proteins as
targets.
Results: Shape and physico-chemical properties of the PGH2 binding sites of the four prostanoid
synthases were analyzed and compared in order to understand the molecular basis of the
specificity. This study provides models with predicted pockets for the binding of PGH2 with PGD,
PGE, PGF and PGI Synthases. The results closely match with available experimental data. The
comparison showed seven physico-chemical features that are common to the four PGH2 binding
sites. However this common pattern is not statistically unique and is not specific enough to
distinguish between proteins that can or cannot bind PGH2. A large scale search in ASTRAL data
bank, a non redundant Protein Data Bank, for a similar pattern showed the uniqueness of each of
the PGH2 binding site in these Synthases.
Conclusion: The binding pockets in PGDS, PGES, PGFS and PGIS are unique and do not share
significant commonality which can be characterized as a PGH2 binding site. Local comparison of
these protein structures highlights a case of convergent evolution in analogous functional sites
Background
The Cyclooxygenase (COX) pathway is an important part
of the arachidonic acid (AA) metabolism, generating five
primary prostanoids. The biosynthesis of these prosta-
noids involves a sequence of three-steps namely 1)
Release of arachidonic acid from phospholipids by
secretory, cytoplasmic or from both types of phospho-
lipase A2 (sPLA2 and cPLA2), 2) Oxygenation of AA by
COX enzymes to form prostaglandin endoperoxide H2
(PGH2), and 3) the subsequent conversion of PGH2 to
Prostaglandin D2 (PGD2), Prostaglandin E2 (PGE2),
Prostaglandin F2a (PGF2a), prostacyclin (PGI2), and
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Thromboxane T2 (TXA2) via seven specific synthases
[1,2].
PGD Synthase is responsible for the production of PGD2
as an allergy or inflammation mediator in mast and Th2
cells [5]. There are 3 isoforms of PGE Synthase (PGES)
namely microsomal PGE Synthase -1 (mPGES-1),
microsomal PGE Synthase -2 (mPGES-2) and cytoplas-
mic PGE Synthase (cPGES) responsible for the produc-
tion of PGE2, which is an ultimate mediator of pain and
inflammation. PGE2 also plays a critical role in regulat-
ing renal function and facilitating reproduction [3].
Prostaglandin F2a produced from PGF Synthase (PGFS)
is a hormone-like substance participating in a wide range
of body functions including the contraction and relaxa-
tion of smooth muscle, the dilation and constriction of
blood vessels, control of blood pressure, and modula-
tion of inflammation. PGF2a is used for the induction of
abortion, for evacuation of the uterus after a missed
abortion [4]. PGI2 produced by PGIS, and TXA2
produced by TXAS, are critical for the maintenance of
homeostasis in the vascular tissue [6,7]. Since these five
synthases, are involved in various important biological
processes, they are potential drug targets and drugs are
already in the market for the inhibition of PGDS, PGFS,
PGIS and TXAS. mPGES-1 is being sought after as a novel
target to relieve pain and inflammation after the with-
drawal of popular COX-2 inhibitors from the market [8].
Understanding the interactions of PGH2 with these
synthases and characterizing their binding sites is crucial
for developing novel drugs and also to check for cross
reactivity. PGH2 is an unstable compound and there are
no structures of synthases available in the Protein Data
Bank (PDB) [9] with it. In this paper, the PGH2 binding
sites in these proteins were predicted using the Patch-
Dock algorithm [10]. The predicted binding sites were
then compared using MultiBind [11], a multiple binding
site alignment tool to look for common pattern which
might help us to characterize a PGH2 binding site.
Methods
Protein structure
The crystal structure of four of the proteins namely
PGDS, PGES, PGFS and PGIS are available in the PBD,
while such a structure is not available for mPGES-1,
cPGES and TXAS. For the purpose of docking studies the
following structures were used: (i) PGDS - The structure
of human hematopoietic prostaglandin D synthase
complexed with HQL-79 (PDB: 2cvd, [12]). (ii) PGES -
The structure of Microsomal prostaglandin E synthase
type-2 (PDB: 1z9h, [13]). (iii)PGFS - The structure of
prostaglandin F synathase containing bimatoprost (PDB:
2f38, [14]) and (iv) PGIS - The structure of human
prostacyclin synthase in complex with inhibitor minox-
idil (PDB: 3b6h, [15]).
Docking
The dockings of PGH2 with these synthases were
performed to predict the putative binding site in the
proteins. Docking models are obtained using the
PatchDock algorithm [10]. This software takes two
molecules as input and computes the three-dimensional
transformation of one of them with respect to the other
with the goal of maximizing the surface shape comple-
mentarities and at the same time minimizing the
number of steric clashes. Given two molecules, Patch-
Dock first divides their surfaces into patches according to
their surface shape, such as concave, convex, or flat.
Then, it applies the Geometric Hashing algorithm to
match the concave patches of one with the convex
patches of the other protein and flat patches with flat
patches and generates a set of candidate transformations.
A set of scoring functions based on the shape comple-
mentarities and the atomic desolvation energy of the
transformed complex is evaluated. Finally, redundant
solutions are discarded by the application of a RMSD
(root-mean-square deviation) clustering. This program is
tested and shown to successfully predict protein interac-
tions for many examples [16-19].
Binding site alignment
The alignment of these predicted binding sites for PGH2
in the four synthases was performed using the MultiBind
algorithm developed by Shulmana et. al [11].
This algorithm performs multiple alignments of the
binding sites and recognizes the structurally conserved
physicochemical and geometrical patterns that may be
responsible for the binding. The physicochemical prop-
erties considered by the software are hydrophobic,
aliphatic (ALI) and aromatic interactions (PII), hydrogen
bond donors (DON), hydrogen bond acceptors (ACC),
and mixed donor/acceptors (DAC). The algorithm finds
a set of transformations which will superimpose the
binding sites in a manner that will maximize the
physicochemical score of the matched properties. This
alignment between protein binding sites is performed
even in the absence of overall sequence, fold, or binding
partner similarity, and also it does not consider the
location of the binding partners. The scoring function
and the algorithm of MultiBind are described in detail
elsewhere [11].
Evaluation of common binding patterns
The frequency of random occurrence of structural
patterns as recognized by MultiBind is searched with
proteins in the ASTRAL dataset (V 1.73) [20,21]. This
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dataset consists of all known protein structures that have
less than 40% sequence identity and hence it represents a
non-redundant group. This dataset contains only the
structures of PGDS and mPGES-2 that are known to bind
to PGH2. The other two structures namely PGFS and
PGIS were added to make the dataset of 7649 structures
in which four of them were known to bind PGH2. The
structural pattern was chosen from the pseudocenters of
the first molecule in the input order. Each pattern that
was recognized on the surface of some other protein was
scored using the physicochemical scoring function of
MultiBind as explained before. The frequency of occur-
rence of a pattern was calculated as the ratio between the
numbers of times it was observed with a score higher
than a reference score, relative to the total number of
searched proteins. The reference score is defined to be
the score of the outlier, i.e., lowest score of the most
different binding site that participated in the pattern
construction with MultiBind.(Example: If A, B, C and D
are the protein compared, and the binding sites of A and
D differ the most with the least MultiBind Score then
that is taken as the reference score for comparisons of
ABCD, ABD, ACD and AD with the ASTRAL dataset). The
obtained ratio represents the estimation of the chances
for a random occurrence of the recognized pattern. Using
the score of the outlier as a reference score provides the
highest possible ratio and the worst case estimation of
the most frequent pattern [16]. The ratio of the number
of similar patterns observed relative to the size of the
searched dataset provides an estimation of the prob-
ability of observing such a pattern by chance, on a
randomly selected protein. The lower the frequency of
occurrence, rare is the pattern.
Results
Docking models of PGH2 with four synthases
PatchDock successfully detected the surface pockets of
PGDS, PGES, PGFS and PGIS and they are in agreement
with previously published data [22-30]on the putative
binding site of PGH2. In all these analysis no apriori
information was used as an input for the docking
algorithms, i.e., the surface pockets on the receptor
molecules were detected automatically.
For all the four synthases, out of the 20 docking
solutions examined the putative binding site was
predominantly located as the possible preferred binding
pocket (in 16, 15, 15, 13 cases out of 20 solutions for
PGFS, PGES, PGDS and PGIS respectively). A compar-
ison between the predicted PGH2 binding site and the
ligand binding site in crystal structures of these four
structures suggested that in all the four cases the ligand
bound in the crystal structure actually fits in the PGH2
binding pocket predicted in the current study. Based on
residues extracted within 6Ǻ distance from the bound
PGH2 and Ligand, it was found that common amino
acid residues participated in the binding of PGH2 to the
synthases in the docked model and the ligand in the
crystal structure obtained from PDB Among the common
residues, the cofactors GSH, NADP and HEME involved
in the catalytic mechanism of the synthases PGDS (GSH)
[12], PGFS (NADP) [14] and PGIS (HEME) [15]
respectively are also shown in Figure 1.
Binding site alignment and analysis
After obtaining the docking models and information
about the PGH2 binding pocket, the goal was to compare
these four predicted binding pockets and to determine
the common features which facilitate the binding of the
same substrate, PGH2.
The four binding sites compared here have different
overall sequences and conserved residue patterns and are
also structurally not related. Due to the above-men-
tioned differences, the proteins in this study cannot be
aligned by standard alignment methods, that assume
similarity of either sequence or backbone patterns. Thus,
to compare between the predicted binding sites of the
modelled complexes, we used MultiBind which performs
a multiple structure alignment between protein binding
Figure 1
Overlap of predicted PGH2 binding site with the
ligand binding site in the four synthases. The surface of
the synthases are represented in cartoon and colored grey
except the common active site residues represented in
space-fill and are colored green. PGH2 is colored red, and
the other ligands in the crystal structure (IMN, HQL-79, 15
M and MDX) are colored blue. The figure is prepared using
PyMol [36]
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sites, in the absence of overall sequence, fold, or binding
partner similarity and recognizes the common spatial
arrangements of physicochemical properties shared
between the compared binding sites. The ligand from
the crystal structures were used to extract the binding site
pocket with the MULTIBIND algorithm rather with the
PGH2 docked models as the algorithm do not accept
docked models as input.
Multiple alignment of all the four binding sites
Alignment of all the four binding sites of PGH2 indicated a
common pattern of seven physicochemical properties,
namely one hydrogen bond acceptor/donor (DAC), three
PII interactions, and three aliphatic interactions (ALI).
Table 1 lists the residue numbers, residue types and the
common physiochemical parameters identified for each of
the four binding sites. Although the substrate PGH2, the
ligand and its interactions with the protein were not taken
into account during any of the computational steps
performed by MultiBind, it never-the-less detected the
key residues thought to be involved in the catalytic
mechanism and superimposed the ligand molecules to
similar locations in space, supporting the correctness of the
alignment.(Figure 2). However this common pattern when
searched for was found in 11% of the proteins in the
ASTRAL dataset. This suggests that the detected pattern is
not likely to be specific enough to distinguish between
proteins that can and those that cannot bind PGH2.
Multiple alignments of three binding sites
The alignment between all the four binding sites resulted
in a common pattern with seven physiochemical proper-
ties that is not unique enough for identification of the
binding of PGH2. Therefore binding sites were aligned,
eliminating one synthase at a time from the MultiBind
during run time.
Comparison between three predicted binding sites of
PGH2 at a time revealed a pattern of between 6-8
common physicochemical properties. The frequency of
occurrence of this pattern in the ASTRAL dataset ranged
between 17-38% showing that the frequency of occur-
rence of this pattern in this dataset is also too high to be
statistically significant and once again it can be
concluded that it is not specific enough to distinguish
between proteins that can or cannot bind PGH2.
Table 1: Details of the common pattern calculated between the four PGH2 binding sites using MultiBind. PII (aromatic) interactions,
hydrogen bond acceptor (ACC), or mixed donor-acceptor (DON, DAC) and Aliphatic interactions(ALI)
Site 1: PGES/1z9hB Site 2: PGDS/2cvdD Site 3:PGFS/2f38A Site 4: PGIS/3b6hA
Chain.ID A. A. Type C
hain.ID
A. A. Type Chain.ID A. A. Type Chain.ID A. A. Type
B.107 Tyr PII D.9 Phe PII A.24 Tyr PII A.99 Tyr PII
B.109 Thr PII D.13 Gly PII A.117 His PII A.283 Ala PII
B.109 Thr ACC D.13 Gly ACC A.117 His DAC A.283 Ala ACC
B.110 Cys ALI D.14 Arg ALI A.54 Leu ALI A.283 Ala ALI
B.246 Ile ALI D.99 Met ALI A.120 Met ALI A.128 Leu ALI
B.250 Val ALI D.160 Leu ALI A.318 Pro ALI A.447 Ala ALI
B.251 Tyr PII D.163 Phe PII A.319 Tyr PII A.434 Trp PII
Figure 2
Superimposition of the four synthases based on
transformations suggested by MultiBind. Spatial
arrangement of the recognized features and the
superimposition of the proteins and the PGH2 ligands,
according to the transformations suggested by MultiBind.
The structures of the four proteins are represented by
strands. PGDS - blue, PGES - red, PGFS - green and PGIS -
gray. PGH2 are represented as space fill and colored
according to the protein. The ligand molecules are presented
for verification purpose only and are not a part of the input
to MultiBind. The figure is prepared using PyMol [36]
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Pairwise alignments
Pairwise surface alignments of the proteins detected
more common features than those obtained while
aligning three or four binding sites at a time. The
summary of the six pairwise alignments of PGH2 binding
sites is listed in Table 2. The two binding sites that were
recognized to be most similar to each other are those of
PGFS and PGIS. As can be seen from the similarity score,
the binding site of the PGDS was the most different from
all the rest. The number of common properties varies
between 10 and 18. The occurrences of the common
patterns based on the 6 pairwise alignments in the
ASTRAL dataset ranges from 3 to 12% again indicating
the uniqueness of each PGH2 binding site. This confirms
that the PGH2 binding site of these four Synthases differ
considerably and are also very different from any other
binding pocket found on the proteins in the ASTRAL
dataset.
Discussion
Based on the MultiBind similarity score, PGDS-PGFS is
ranked second. PGFS is a dual acting enzyme leading to
the formation of both PGF2a from PGH2 and 9a,11b-
PGF2 (PGF2ab) from PGD2. It can bind to both PGH2
and PGD2 [15]. The former is converted to PGD2 by
PGDS; the later remains bound to the enzyme before
being released. Having two common binding partners
possibly explains their high similarity. It is surprising to
note that both PGDS and PGES belonging to the same
family with similar catalytic mechanism has the least
number (11) of common features and are among the
most different from each other when compared with
other synthases. This is followed by PGIS-PGDS having
12 common features. mPGES-2 on the other hand is
found to be more similar to PGIS which is a heme bound
enzyme, than to PGDS. This can be explained based on a
more recently solved structure in which PGES (PDBID:
2pbj[31]) is found to contain glutathione (GSH) and
heme bound to it and it is involved in degradation
reactions similar to that of cytochrome P450. It degrades
PGH2 into 12(S)-hydroxy-5(Z), 8(E),10(E)-heptadeca-
trienoic acid and malondialdehyde rather than convert-
ing it to PGE2 [31].
Interestingly all the seven Prostanoid synthases which bind
to the same substrate PGH2, do not share any sequence
identity amongst them, are structurally quite different and
belong to different families (Figure 3). Yet they share PGH2
as the common binding partner. They even carry out the
similar isomerization reaction at the cyclopentane ring of
PGH2. A divergent evolutionary relation between PGDS and
mPGES-2 and PGIS and TXASmight explain their specificity
but in the other apparently disconnected families it is
unlikely that divergent evolution would have played a role.
Our comparison study shows that it is unlikely, that
identical active site constellations are responsible for
PGH2 specificity in these seven cases. Convergence seems
to be limited to similarity in the ability to bind PGH2
specifically and may not extend to the precise way in which
this is achieved as indicated by the lack of similarity which
can be characterized as a PGH2 binding site. To answer these
questions definitively we need much more biochemical
information about each of the enzymes, details of the
catalytic mechanism, rate constants, quantitative specifici-
ties, and regulatory dependencies.
But evolution of similar enzymatic function on different
structural frameworks is not an entirely uncommon
event. A classical example is that of serine proteases: the
Ser-His-Asp triad is present in an almost identical three-
dimensional constellation in the distinctly different
structural frames of trypsin and subtilisin (and their
relatives) [32,33]. Another example is each of the three
families of sugar kinases which appear to have a distinct
three-dimensional fold, and conserved sequence patterns
are strikingly different for the three families. Yet each
catalyzes chemically equivalent reactions on similar or
identical substrates. The enzymatic function of sugar
phosphorylation appears to have evolved independently
on the three distinct structural frameworks, by conver-
gent evolution[33]. Another aspect which needs con-
sideration is that these proteins can rearrange and
undergo conformational changes to accommodate the
substrate. In practice, both the side-chains and the
protein backbone can undergo conformational changes
upon substrate binding. Even the PGH2 molecule with
14 torsional degrees of freedom of rotation is highly
flexible and can fit into different active sites differently.
Also both the docking and the alignment algorithms
used in the current study considers rigid conformations
and do not address the possibility of protein and
substrate flexibility.
In summary, the Prostanoid Synthases present a remark-
able diversity of specificities for the binding of PGH2. The
discovery of this striking molecular dissimilarity, associated
to a functional substrate similarity, may help in suggesting
new experiments aimed at a deeper understanding of
the cross reactivity of Prostanoid synthases known to be
Table 2: Pairwise alignments of PGH2 binding sites using
MultiBind
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Figure 3
Family and reaction details of the seven prostaglandin synthases. *Reaction Schemes taken from the Kegg Database
[37]
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involved in many important biological processes and
human diseases.
Conclusion
A computational approach was employed to understand
the interaction of PGH2 with the prostaglandin
synthases. Docking models were consistent with the
available experimental data for the interaction of PGH2
with the synthases. The spatial and physicochemical
properties of the suggested binding sites were compared.
A patterns common to all the four synthases was
detected but it was not specific enough and was not
likely to represent the features essential for the binding
of PGH2. The alignment results suggest that the PGH2
binding sites are different on different proteins and they
also have no close similarity with any other binding site
found in the proteins of the ASTRAL dataset.
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